The angiogenic switch leads to a metabolic shift in human glioblastoma

Neuro-Oncology

Volumn 19, Issue 3, 2017, Pages 383-393

  Talasila, Krishna M ^a   Røsland, Gro V ^a   Hagland, Hanne R ^a   Eskilsson, Eskil ^b   Flønes, Irene H ^c   Fritah, Sabrina ^d   Azuaje, Francisco ^d   Atai, Nadia ^e   Harter, Patrick N ^f,g   Mittelbronn, Michel ^f,g   Andersen, Michael ^c   Joseph, Justin V ^a   Al Hossain, Jubayer ^a,c   Vallar, Laurent ^d   Van Noorden, Cornelis J F ^e   Niclou, Simone P ^a,d   Thorsen, Frits ^a   Tronstad, Karl Johan ^a   Tzoulis, Charalampos ^c   Bjerkvig, Rolf ^a,c   Miletic, Hrvoje ^a,c   more..

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF TEXAS   (United States)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f GOETHE UNIVERSITY   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Angiogenesis; Glioblastoma; Glycolysis; Hypoxia; Invasion

Indexed keywords

GLUCOSE TRANSPORTER 1; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE A; LACTIC ACID; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BHLHE40; TRANSCRIPTION FACTOR CEBPB; UNCLASSIFIED DRUG;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRONEURAL MESENCHYMAL TRANSITION; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR HYPOXIA; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; CELL HYPOXIA; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE RAT; PATHOLOGY; RAT; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE; VASCULARIZATION;

ANIMALS; BRAIN NEOPLASMS; CELL HYPOXIA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLYCOLYSIS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, NUDE; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019724359     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now175     Document Type: Article

References (48)

1. Louis D, Ohgaki H, Wiestler O, et al. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007.
2. Zeng W, Liu P, Pan W, et al. Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 2015;356(2 Pt A):263-267.
3. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
5. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325-337.
6. Marin-Valencia I, Yang C, Mashimo T, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15(6):827-837.
7. Navis AC, Niclou S P, Fack F, et al. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and alpha-KG. Acta Neuropathol Commun. 2013;1(1):18.
8. Talasila KM, Soentgerath A, Euskirchen P, et al. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 2013;125(5):683-698.
9. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
10. Madhavan S, Zenklusen JC, Kotliarov Y, et al. Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res.: MCR. 2009;7(2):157-167.
11. Bjerkvig R, Tonnesen A, Laerum OD, et al. Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg. 1990;72(3):463-475.
12. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272(5259):263-267.
13. Sakariassen PO, Prestegarden L, Wang J, et al. Angiogenesisindependent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A. 2006;103(44):16466-16471.
14. Philippidou D, Schmitt M, Moser D, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010;70(10):4163-4173.
15. Perez-Llamas C, Lopez-Bigas N. Gitools: analysis and visualisation of genomic data using interactive heat-maps. PLoS One. 2011;6(5):e19541.
16. Wang J, Duncan D, Shi Z, et al. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41(Web Server issue):W77-83.
17. Supek F, Bosnjak M, Skunca N, et al. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One. 2011;6(7):e21800.
18. Sun J, Gong X, Purow B, et al. Uncovering microRNA and transcription factor mediated regulatory networks in glioblastoma. PLoS Comput Biol. 2012;8(7):e1002488.
19. Cline MS, Smoot M, Cerami E, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007;2(10):2366-2382.
20. Huttenhower C, Haley EM, Hibbs MA, et al. Exploring the human genome with functional maps. Genome Res. 2009;19(6):1093-1106.
21. Baumgarten P, Harter PN, Tonjes M, et al. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. Neuropathol Appl Neurobiol. 2014;40(2):205-216.
22. Molenaar RJ, Botman D, Smits MA, et al. Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant Inhibitor AGI-5198. Cancer Res. 2015;75(22):4790-4802.
23. Yang Y, Balcarcel RR. 96-well plate assay for sublethal metabolic activity. Assay Drug Dev Technol. 2004;2(4):353-361.
24. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14(4):260-264.
25. Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010;463(7279):318-325.
26. Cooper LA, Gutman DA, Chisolm C, et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol. 2012;180(5):2108-2119.
27. Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011;208(2):313-326.
28. Zhou Y, Zhou Y, Shingu T, et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem. 2011;286(37):32843-32853.
29. Jelluma N, Yang X, Stokoe D, et al. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res: MCR. 2006;4(5):319-330.
30. Deighton RF, Le Bihan T, Martin SF, et al. Interactions among mitochondrial proteins altered in glioblastoma. J Neurooncol. 2014;118(2):247-256.
31. Iommarini L, Calvaruso MA, Kurelac I, et al. Complex I impairment in mitochondrial diseases and cancer: parallel roads leading to different outcomes. Int J Biochem Cell Biol. 2013;45(1):47-63.
32. Barrientos A, Moraes CT. Titrating the effects of mitochondrial complex I impairment in the cell physiology. J Biol Chem. 1999;274(23):16188-16197.
33. Hagland H, Nikolaisen J, Hodneland LI, et al. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert Opin Ther Targets. 2007;11(8):1055-1069.
34. Yang C, Sudderth J, Dang T, et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69(20):7986-7993.
35. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A. 2011;108(9):3749-3754.
36. Beckner ME, Chen X, An J, et al. Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab Invest. 2005;85(3):316-327.
37. Wang J, Miletic H, Sakariassen PO, et al. A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer. 2009;9:465.
38. Shiraishi T, Verdone JE, Huang J, et al. Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget. 2015;6(1):130-143.
39. Beckner ME, Stracke ML, Liotta LA, et al. Glycolysis as primary energy source in tumor cell chemotaxis. J Natl Cancer Inst. 1990;82(23):1836-1840.
40. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
41. Li J, Taich ZJ, Goyal A, et al. Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. Oncotarget. 2014;5(17):7342-7356.
42. Talasila KM, Brekka N, Mangseth K, et al. Tumor versus stromal cells in culture-survival of the fttest? PLoS One. 2013;8(12):e81183.
43. Halliday J, Helmy K, Pattwell SS, et al. In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. Proc Natl Acad Sci U S A. 2014;111(14):5248-5253.
44. Bhat K P, Balasubramaniyan V, Vaillant B, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell. 2013;24(3):331-346.
45. Piao Y, Liang J, Holmes L, et al. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013;19(16):4392-4403.
46. Ozawa T, Riester M, Cheng YK, et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 2014;26(2):288-300.
47. Murat A, Migliavacca E, Hussain SF, et al. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One. 2009;4(6):e5947.
48. Naef F, Huelsken J. Cell-type-specific transcriptomics in chimeric models using transcriptome-based masks. Nucleic Acids Res. 2005;33(13):e111.